The reproducibility and consistency of these results have been demonstrated across multiple databases, tumor types, various methods, and omics analyses, suggesting that the dysregulation of R3HDM1 expression may be involved in different cancers and is unlikely to be attributed to technical artifacts, randomness, or biases in sample identification standards within databases. Here, R3HDM1 is linked to neoplasm.